T-Cells Modified with CD70 as an Alternative Cellular Vaccine for Antitumor Immunity
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Successful tumor eradication primarily depends on generation and maintenance of a large population of tumor-reactive CD8 T cells. Dendritic cells (DCs) are well-known potent antigen- presenting cells and have applied to clinics as potent antitumor therapeutic agents. However, high cost and difficulty in obtaining sufficient amounts for clinical use are the crucial drawbacks of DC-based vaccines. Here, we aimed to develop T cell–based vaccine capable of eliciting potent antitumor therapeutic effects by providing effective costimulatory signals. Materials and Methods Antigenic peptide-loaded T cells transfected with retrovirus encoding costimulatory ligands CD70, CD80, OX40L, or 4-1BBL were assessed for antigen-specific CD8 T-cell responses and evaluated antitumor effects along with immunization of a mixture of synthetic peptides, poly-IC and anti-CD40 antibodies (TriVax). Results T cells expressing CD70 (CD70-T) exhibited similar level of stimulatory functionality and therapeutic efficacy as DCs. Moreover, CD70-T prime followed by TriVax booster heterologous vaccination elicited therapeutic antitumor effect against B16 melanoma where mediated by CD8 T cells but not CD4 T cells or natural killer cells. The combination with programmed death-ligand 1 blockade led to potent therapeutic efficacy which exhibited increased tumor-infiltrating CD8 T cells. CD70-T pulsed with multi-antigenic peptide generated multiple antigen-specific polyvalent CD8 T cells that were capable of inhibiting tumor growth effectively. Moreover, CD70-T vaccination resulted in higher expansion and migration of adoptively transferred T cells into tumor sites and elicits enhanced therapeutic effects with peptide-based booster immu-nization. Conclusion These results imply that T cells endowed with CD70 enable the design of effective vaccination strategies against solid cancer, which may overcome current limitations of DC-based vaccines.
Abstract
Purpose Successful tumor eradication primarily depends on generation and maintenance of a large population of tumor-reactive CD8 T cells. Dendritic cells (DCs) are well-known potent antigen- presenting cells and have applied to clinics as potent antitumor therapeutic agents. However, high cost and difficulty in obtaining sufficient amounts for clinical use are the crucial drawbacks of DC-based vaccines. Here, we aimed to develop T cell–based vaccine capable of eliciting potent antitumor therapeutic effects by providing effective costimulatory signals. Materials and Methods Antigenic peptide-loaded T cells transfected with retrovirus encoding costimulatory ligands CD70, CD80, OX40L, or 4-1BBL were assessed for antigen-specific CD8 T-cell responses and evaluated antitumor effects along with immunization of a mixture of synthetic peptides, poly-IC and anti-CD40 antibodies (TriVax). Results T cells expressing CD70 (CD70-T) exhibited similar level of stimulatory functionality and therapeutic efficacy as DCs. Moreover, CD70-T prime followed by TriVax booster heterologous vaccination elicited therapeutic antitumor effect against B16 melanoma where mediated by CD8 T cells but not CD4 T cells or natural killer cells. The combination with programmed death-ligand 1 blockade led to potent therapeutic efficacy which exhibited increased tumor-infiltrating CD8 T cells. CD70-T pulsed with multi-antigenic peptide generated multiple antigen-specific polyvalent CD8 T cells that were capable of inhibiting tumor growth effectively. Moreover, CD70-T vaccination resulted in higher expansion and migration of adoptively transferred T cells into tumor sites and elicits enhanced therapeutic effects with peptide-based booster immu-nization. Conclusion These results imply that T cells endowed with CD70 enable the design of effective vaccination strategies against solid cancer, which may overcome current limitations of DC-based vaccines.
참고문헌 (38)
- Croft M, "Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?", Nat Rev Immunol, 3, pp.609~620 (2003)
- Thery C, "The cell biology of antigen presentation in dendritic cells", Curr Opin Immunol, 13, pp.45~51 (2001)
- Cho HI, "An optimized peptide vaccine strategy capable of inducing multivalent CD8(+)T cell responses with potent antitumor effects", Oncoimmunology, 4, pp.e1043504~ (2015)
- Liu Y, "Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+)cytotoxic T-cell activation and antitumor immunity", Cancer Gene Ther, 9, pp.202~208 (2002)
- Mende I, "Breaking tolerance to tumors with dendritic cell-based immunotherapy", Ann N Y Acad Sci, 1058, pp.96~104 (2005)
- Steinman RM, "Dendritic cells : antigen presentation, accessory function and clinical relevance", Adv Exp Med Biol, 329, pp.1~9 (1993)
- Turnis ME, "Enhancement of dendritic cells as vaccines for cancer", Immunotherapy, 2, pp.847~862 (2010)
- Shin CA, "Co-expression of CD40L with CD70 or OX40L increases B-cell viability and antitumor efficacy", Oncotarget, 7, pp.46173~46186 (2016)
- Guo S, "Induction of protective cytotoxic T-cell responses by a B-cell-based cellular vaccine requires stable expression of antigen", Gene Ther, 16, pp.1300~1313 (2009)
- Park MY, "Efficient antitumor immunity in a murine colorectal cancer model induced by CEA RNA-electroporated B cells", Eur J Immunol, 38, pp.2106~2117 (2008)
- Kim YJ, "alpha-Galactosylceramide-loaded, antigen-expressing B cells prime a wide spectrum of antitumor immunity", Int J Cancer, 122, pp.2774~2783 (2008)
- Chung Y, "CD1drestricted T cells license B cells to generate long-lasting cytotoxic antitumor immunity in vivo", Cancer Res, 66, pp.6843~6850 (2006)
- Himoudi N, "Human gammadelta T lymphocytes are licensed for professional antigen presentation by interaction with opsonized target cells", J Immunol, 188, pp.1708~1716 (2012)
- Kennedy R, "Direct cross-priming by th lymphocytes generates memory cytotoxic T cell responses", J Immunol, 174, pp.3967~3977 (2005)
- Adamopoulou E, "Human CD4+ T cells displaying viral epitopes elicit a functional virus-specific memory CD8+ T cell response", J Immunol, 178, pp.5465~5472 (2007)
- Park HM, "CD4 T-cells transduced with CD80 and 4-1BBL mRNA induce long-term CD8 T-cell responses resulting in potent antitumor effects", Vaccine, 32, pp.6919~6926 (2014)
- Croft M, "Costimulation of T cells by OX40, 4-1BB, and CD27", Cytokine Growth Factor Rev, 14, pp.265~273 (2003)
- Driessens G, "Costimulatory and coinhibitory receptors in anti-tumor immunity", Immunol Rev, 229, pp.126~144 (2009)
- Johnson BD, "Neuroblastoma cells transiently transfected to simultaneously express the co-stimulatory molecules CD54, CD80, CD86, and CD137L generate antitumor immunity in mice", J Immunother, 28, pp.449~460 (2005)
- Overwijk WW, "Tumor regression and autoimmunity after reversal of a functionally tolerant state of selfreactive CD8+ T cells", J Exp Med, 198, pp.569~580 (2003)
- Garrigan K, "Functional comparison of spleen dendritic cells and dendritic cells cultured in vitro from bone marrow precursors", Blood, 88, pp.3508~3512 (1996)
- Datta J, "Optimizing dendritic cell-based approaches for cancer immunotherapy", Yale J Biol Med, 87, pp.491~518 (2014)
- Amir-Hassan Zarnani, "Improved Efficacy of a Dendritic Cell-Based Vaccine against a Murine Model of Colon Cancer: The Helper Protein Effect", Cancer Research and Treatment, 47(3), pp.518~526 (2015), 대한암학회[DOI]
- Cho HI, "Enhanced induction of anti-tumor immunity in human and mouse by dendritic cells pulsed with recombinant TAT fused human survivin protein", Cancer Lett, 258, pp.189~198 (2007)
- Watts TH, "T cell costimulatory molecules in anti-viral immunity : Potential role in immunotherapeutic vaccines", Can J Infect Dis, 14, pp.221~229 (2003)
- Arens R, "Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8+T cell formation", J Exp Med, 199, pp.1595~1605 (2004)
- Sharpe AH, "The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection", Nat Immunol, 8, pp.239~245 (2007)
- Duraiswamy J, "Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors", Cancer Res, 73, pp.3591~3603 (2013)
- Mumprecht S, "Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression", Blood, 114, pp.1528~1536 (2009)
- Pilon-Thomas S, "Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma", J Immunol, 184, pp.3442~3449 (2010)
- Landsberg J, "Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation", Nature, 490, pp.412~416 (2012)
- Mehrotra S, "Vaccination with poly(IC : LC)and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer", J Hematol Oncol, 10, pp.82~ (2017)
- Aravantinou M, "PolyICLC exerts pro-and anti-HIV effects on the DC-T cell milieu in vitro and in vivo", PLoS One, 11, pp.e0161730~ (2016)
- Johnson P, "Clinical and biological effects of an agonist anti-CD40antibody : a Cancer Research UK phase I study", Clin Cancer Res, 21, pp.1321~1328 (2015)
- Bajor DL, "Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma", Oncoimmunology, 7, pp.e1468956~ (2018)
- Kumai T, "Cancer immunotherapy : moving forward with peptide T cell vaccines", Curr Opin Immunol, 47, pp.57~63 (2017)
- Hirayama M, "The present status and future prospects of peptide-based cancer vaccines", Int Immunol, 28, pp.319~328 (2016)
- Peng M, "Neoantigen vaccine : an emerging tumor immunotherapy", Mol Cancer, 18, pp.128~ (2019)